큐라티스
2016.07.15
  • Established “Quratis”
  • Equity investment: KRW 0.9 Billion
  • Business area: Vaccines and Immunological therapeutics
2016.09.13
  • Capital increase : Equity investment KRW 1 Billion
2016.09.23
  • Signed Collaboration & Clinical Supply Agreement with IDRI
2016.12.19
  • Recognized for the company auxiliary research center by KOITA
    (Korea Industry & Technology Association)
2016.12.22
  • Signed Master Material Transfer Agreement with IDRI
2017.01.31
  • Selected as the Research-driven hospitals R&D project from the Korean Ministry of
    Health and Welfare, as a sub-project named “Commercialization of a vaccine for accelerating
    the elimination of tuberculosis and low-cost rapid diagnosis of severe infectious diseases.”
2017.02.24
  • Signed with CRO for Phase 2 study of tuberculosis vaccine
*IDRI: Infectious Disease Research Institute, USA